1. Home
  2. TWIN vs AKBA Comparison

TWIN vs AKBA Comparison

Compare TWIN & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$24.85

Market Cap

320.9M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.85

Market Cap

343.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
AKBA
Founded
1918
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
320.9M
343.4M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
TWIN
AKBA
Price
$24.85
$0.85
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.67
AVG Volume (30 Days)
77.6K
3.9M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
0.98%
N/A
EPS Growth
N/A
93.94
EPS
1.76
N/A
Revenue
$340,738,000.00
N/A
Revenue This Year
$10.79
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$14.18
N/A
Revenue Growth
15.45
N/A
52 Week Low
$8.50
$0.81
52 Week High
$25.30
$3.32

Technical Indicators

Market Signals
Indicator
TWIN
AKBA
Relative Strength Index (RSI) 60.09 29.48
Support Level $14.76 $0.85
Resistance Level N/A $1.54
Average True Range (ATR) 0.98 0.07
MACD 0.06 -0.04
Stochastic Oscillator 80.74 7.33

Price Performance

Historical Comparison
TWIN
AKBA

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: